Cingulate Therapeutics

Cingulate Therapeutics is a privately held, clinical-stage biopharmaceutical company utilizing our proprietary Precision Timed Release (PTR) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products aimed at improving the lives of patients with frequently diagnosed conditions. Our initial focus is on treatments for Attention Deficit/Hyperactivity Disorder (ADHD), where the technology enables the formulation and manufacture of once-daily tablets for multi-dose therapies. Cingulate is developing two proprietary first-line stimulant medications, CTx-1301 and CTx-1302, for the treatment of all patient populations. Cingulate is also identifying and evaluating additional therapeutic areas where PTR technology can be used to develop future product candidates.